Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05730842 · ClinicalTrials.gov registry record · Phase 1
Absorption, Metabolism, Excretion and Absolute Bioavailability of EDG-5506 in Healthy Volunteers
A Phase 1 study, sponsored by Edgewise Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 15
- Enrollment target
NCT05730842 is a Phase 1 study that has completed, run by Edgewise Therapeutics. The registered enrollment target is 15 participants.
The verdict
NCT05730842, a Phase 1 study, has completed, sponsored by Edgewise Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 15 participants
- Enrollment target
Study Summary
This is a Phase 1 2-part, single-center, open-label study in healthy male volunteers. Part A will assess the absorption, metabolism, excretion, and pharmacokinetics of one oral dose of radiolabeled EDG-5506. Part B will assess bioavailability of EDG-5506 with a single oral dose of EDG-5506 and a single intravenous dose of radiolabeled EDG-5506.
Interventions
- DRUG EDG-5506 Tablet
- DRUG Radiolabeled EDG-5506 Suspension
- DRUG Radiolabeled EDG-5506 Intravenous
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2023-01-12 |
| Est. Completion | 2023-04-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05730842
The ClinicalTrials.gov registry entry for NCT05730842 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Edgewise Therapeutics, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which EDG-5506 Tablet is the first listed.
NCT05730842 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05730842 about?
NCT05730842 is a clinical study titled "Absorption, Metabolism, Excretion and Absolute Bioavailability of EDG-5506 in Healthy Volunteers". This is a Phase 1 2-part, single-center, open-label study in healthy male volunteers. Part A will assess the absorption, metabolism, excretion, and pharmacokinetics of one oral dose of radiolabeled EDG-5506. Part B will assess bioavailability of EDG-5506 with a single oral dose of EDG-5506 and a sin...
What is the current status of trial NCT05730842?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2023-01-12. Estimated completion is 2023-04-06.
What interventions are being tested in trial NCT05730842?
The interventions under investigation include: EDG-5506 Tablet (DRUG), Radiolabeled EDG-5506 Suspension (DRUG), Radiolabeled EDG-5506 Intravenous (DRUG).
Who is sponsoring clinical trial NCT05730842?
This trial is sponsored by Edgewise Therapeutics, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.